Diabetes mellitus and secondary immunodeficiency

Authors: Daniela Kantárová 1,2;  Mojmír Vrlík 2;  Ivana Ságová 1;  Dana Prídavková 1;  Peter Galajda 1;  Marián Mokáň 1
Authors‘ workplace: I. interná klinika Jesseniovej LF UK a UNM, Martin 1;  Martinské centrum imunológie, Martin 2
Published in: Forum Diab 2016; 5(3): 146-150
Category: Topic


Type 1 and type 2 diabetes mellitus is a complex disorder which affects multiple organs and organ systems, not excluding the immune system. It is quite frequently caused by secondary immunodeficiency – therefore it affects mechanisms of both non-specific (chemotaxis, phagocytosis) and specific immunity (generation and maturation of B- and T-lymphocytes). Diabetes is associated with an increased incidence of infectious diseases – mainly those of the urogenital tract, skin and airways. The course of infections in diabetics is more serious, involving more complications, requiring aggressive treatment and lastly it is associated with higher mortality.

Key words:
diabetes mellitus – complicated infections in patients with diabetes mellitus – non-specific immunity – secondary immunodeficiency – specific immunity


1. Petrů V. Dětská alergologie. Mladá fronta: Praha 2012. ISBN 978–80–204–2584–3.

2. Čižnár P. Nový pohľad na primárne imunodeficiencie. Pediatr prax 2012; 13(6): 249–252.

3. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus. FEMS Immunol Med Microbiol 1999; 26(3–4): 259–265.

4. Pearson-Stuttard J, Blundeli S, Harris T, et al. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol 2016; 4(2): 148–158. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(15)00379–4>.

5. Rubinstein MR, Genaro AM, Wald MR. Differential effect of hyperglycaemia on the immune response in an experimental model of diabetes in BALB/cByJ and C57Bl/6J mice: participation of oxidative stress. Clin Exp Immunol 2013; 171(3): 319–329. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12020>.

6. Stegenga ME, van der Crabben SN, Dessing MC, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 2008; 25(2): 157–164. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2007.02348.x>.

7. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007; 50(3): 549–554.

8. Muller LMAJ, Gorter KL, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41(3): 281–288.

9. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16(Suppl1): S27–S36. Dostupné z DOI: <http://dx.doi.org/10.4103/2230–8210.94253>.

10. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010; 125(2 Suppl 2): S195–203. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2009.08.040>.

11. Peleg AY, Weerarathna T, McCarthy JS et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23(1): 3–13

12. Walrand S, Guillet C, Boirie Y et al. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 2004; 76(6): 1104–1110.

13. Atreja A, Kalra S. Infections in diabetes. J Pak Med Assoc 2015; 65(9): 1028–1030.

14. Galajda P, Mokáň M, Mokáň M. Metabolic syndrome and prediabetic states. Vnitr Lek 2013; 59(6): 453–458.

15. Hirji I, Guo Z, Andersson SW et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications 2012; 26(6): 513–516. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2012.06.008>.

16. Al-Rubeaan KA, Moharram O, Al-Naqeb D et al. Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World J Urol 2013; 31(3): 573–578. Dostupné z DOI: <http://dx.doi.org/10.1007/s00345–012–0934-x>.

17. Renko M, Tapanainen P, Tossavainen P et al. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care 2011; 34(1): 230–235. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–0421>.

18. Nicolle LE, Capuano G, Fung A et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014; 126(1): 7–17. Dostupné z DOI: <http://dx.doi.org/10.3810/pgm.2014.01.2720>.

19. Yang XP, Lai D, Zhong XY et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 2014; 70(10): 1149–58. Dostupné z DOI: <http://dx.doi.org/10.1007/s00228–014–1730-x>.

20. Nitzan O, Elias M, Chazan B et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes 2015; 8: 129–136. Dostupné z DOI: <http://dx.doi.org/10.2147/DMSO.S51792>.

21. Joshi N, Caputo GM, Weitekamp MR et al. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341(25): 1906–1912.

22. Inns T, Millership S, Teare L, et al. Service evaluation of selected risk factors for extended-spectrum beta-lactamase Escherichia coli urinary tract infections: a case-control study. J Hosp Infect 2014; 88(2): 116–119. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhin.2014.07.009>.

23. Workneh MH, Bjune GA, Yimer SA. Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia. Infect Dis Poverty 2016; 5: 22. Dostupné z DOI: <http://dx.doi.org/10.1186/s40249–016–0115-z>.

24. Jenkins TC, Knepper BC, Moore SJ et al. Comparison of the Microbiology and Antibiotic Treatment among Diabetic and Non-Diabetic Patients Hospitalized for Cellulitis or Cutaneous Abscess. J Hosp Med 2014; 9(12): 788–794. <http://dx.doi.org/10.1002/jhm.2267>.

25. Goyal A, Raina S, Kaushal SS et al. Pattern of cutaneous manifestations in diabetes mellitus. Indian J Dermatol 2010; 55(1): 39–41. Dostupné z DOI: <http://dx.doi.org/10.4103/0019–5154.60349>.

26. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med 2015; 13: 53. Dostupné z DOI: <http://dx.doi.org/10.1186/s12916–015–0295–6>.

27. [American Diabetes Association]. Standards of Medical Care in Diabetes—2014. Diabetes Care 2014; 37(Suppl1): S14-S80. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14-S014>.

28. Dankovčíková A. Očkovanie a diabetes mellitus 1. typu. In: Jeseňák M, Urbančíková I (ed). Očkovanie v špeciálnych situáciách. Mladá fronta: Praha 2013: 28–32. ISBN 978–80–204–2805–9.

29. Dankovčíková A. Postup pri očkovaní osôb s diabetom mellitus 1. typu. In: Jeseňák M, Urbančíková I (ed). Očkovanie v špeciálnych situáciách. Mladá fronta: Praha 2013: 33–36. ISBN 978–80–204–2805–9.

30. Lau D, Eurich DT, Majumdar SR, et al. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax 2013; 68(7): 658–663. Dostupné z DOI: <http://dx.doi.org/10.1136/thoraxjnl-2012–203109>.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account